scholarly journals Multipoint Costriking Nanodevice Eliminates Primary Tumor Cells and Associated‐Circulating Tumor Cells for Enhancing Metastasis Inhibition and Therapeutic Effect on HCC

2022 ◽  
pp. 2101472
Author(s):  
Weiwei Mu ◽  
Qihui Chu ◽  
Huizhen Yang ◽  
Li Guan ◽  
Shunli Fu ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Therapeutic Effect ◽  
Primary Tumor ◽  
Metastasis Inhibition

scholarly journals Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases

2017 ◽  
Vol 24 (8) ◽  
pp. 2113-2121 ◽  
Author(s):  
Lars Thomas Seeberg ◽  
Cathrine Brunborg ◽  
Anne Waage ◽  
Harald Hugenschmidt ◽  
Anne Renolen ◽  
...  
Keyword(s):  
Lymph Node ◽  
Liver Metastases ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor ◽  
Colorectal Liver Metastases ◽  
Lymph Node Status ◽  
Node Status

Abstract 1726: Evaluation of PD-L1/PD-1 on circulating tumor cells (CTCs) and on primary tumor in advanced non-small cell lung cancer (NSCLC)

2017 ◽  
Author(s):  
Galaktea Kallergi ◽  
Eleni Kyriaki Vetsika ◽  
Despoina Aggouraki ◽  
Eleni Lagoudaki ◽  
Anastasios Koutsopoulos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Correction: Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer

Oncogene ◽  
2019 ◽  
Vol 38 (28) ◽  
pp. 5740-5741 ◽  
Author(s):  
Qihan Fu ◽  
Qi Zhang ◽  
Yu Lou ◽  
Jiaqi Yang ◽  
Gang Nie ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor

Prospective study with circulating tumor cells as potential prognosis biomarker in metastatic colorectal cancer.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 203-203 ◽  
Author(s):  
Virgilio Souza E Silva ◽  
Emne Ali Abdallah ◽  
Celso Abdon Lopes de Mello ◽  
Milena Shizue Tariki ◽  
Vinicius Fernando Calsavara ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prospective Study ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor ◽  
Progression Free Survival ◽  
Blood Collection ◽  
Multidrug Resistance Protein 1 ◽  
Promising Tool ◽  
The Right

203 Background: Colorectal cancer (CRC) is one of the most common cancer worldwide. Around 30% present metastatic disease at diagnosis and 50%–60% of patients develop metastasis. New prognostic markers are needed and circulating tumor cells (CTCs) are a promising tool. Methods: Prospective study conducted by blood collection from 75 patients (pts) with metastatic CRC (mCRC), twice, with 2 months interval, together with image exams for therapeutic response evaluation. CTCs were detected by ISET and identified by immunocytochemistry. Results: The mean age was 57.3 years old (24-81). RAS mutations in primary tumor was found in 38% (19/50) of patients (pts) and left colon topography in 41.3% (31/75). Comparing the baseline CTC level (CTC1) with the level at first follow-up (CTC 2), pts with CTC2 – CTC1 > 5.5 per ml demonstrated poor progression-free survival (PFS) (3.2 months) when compared to CTC 2 – CTC1 ≤ 5.5 (9.1 months) (p= 0.005). The median overall survival (OS) was 24.5 months for pts with CTC 1 > 1.5 per ml and 34.2 months for those with CTC1 ≤ 1.5 per (HR=1.89, 95% CI, 1.01 to 3.52; p= 0.041). Patients with RAS mutation (P= 0.001), primary tumor in the right colon (p= 0.014) and expression of Multidrug Resistance Protein 1 in CTCs (p= 0.044) had worse OS. By multivariable analyses, CTC 1 > 1.5/mL (p= 0.025) was an independent prognostic factor. Conclusions: This prospective study confirmed that counts of CTCs at baseline (CTC1) is an important prognostic marker for monitoring mCRC and correlates with other established prognostic factors. Clinical trial information: NCT02979470.

The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer

2011 ◽  
Vol 71 (08) ◽  
Author(s):  
FA Taran ◽  
A Hartkopf ◽  
M Banys ◽  
N Krawczyk ◽  
S Becker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor ◽  
Primary Breast Cancer

scholarly journals Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells

Cells ◽  
2019 ◽  
Vol 8 (6) ◽  
pp. 618 ◽  
Author(s):  
Jeannette Huaman ◽  
Michelle Naidoo ◽  
Xingxing Zang ◽  
Olorunseun O. Ogunwobi
Keyword(s):  
Mouse Model ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor ◽  
Cancer Metastasis ◽  
Epithelial To Mesenchymal Transition ◽  
Castration Resistant Prostate Cancer ◽  
Good Tool ◽  
Mesenchymal Transition ◽  
Syngeneic Mouse Model

Metastasis is the leading cause of cancer death worldwide. Circulating tumor cells (CTCs) are a critical step in the metastatic cascade and a good tool to study this process. We isolated CTCs from a syngeneic mouse model of hepatocellular carcinoma (HCC) and a human xenograft mouse model of castration-resistant prostate cancer (CRPC). From these models, novel primary tumor and CTC cell lines were established. CTCs exhibited greater migration than primary tumor-derived cells, as well as epithelial-to-mesenchymal transition (EMT), as observed from decreased E-cadherin and increased SLUG and fibronectin expression. Additionally, when fibronectin was knocked down in CTCs, integrin B1 and SLUG were decreased, indicating regulation of these molecules by fibronectin. Investigation of cell surface molecules and secreted cytokines conferring immunomodulatory advantage to CTCs revealed decreased major histocompatibility complex class I (MHCI) expression and decreased endostatin, C-X-C motif chemokine 5 (CXCL5), and proliferin secretion by CTCs. Taken together, these findings indicate that CTCs exhibit distinct characteristics from primary tumor-derived cells. Furthermore, CTCs demonstrate enhanced migration in part through fibronectin regulation of integrin B1 and SLUG. Further study of CTC biology will likely uncover additional important mechanisms of cancer metastasis.

Use of HER2 amplification in the primary tumor to predict presence of circulating tumor cells in inflammatory breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11133-e11133
Author(s):  
A. Bhattacharyya ◽  
S. Krishnamurthy ◽  
A. Lodhi ◽  
C. Hall ◽  
A. Anderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Inflammatory Breast Cancer ◽  
Primary Tumor ◽  
Her2 Amplification
Sign in / Sign up

Export Citation Format

Share Document